Shares in Cardio3 Biosciences SA gained almost 6 percent Monday on news that the company raised €25 million (US$33.9 million) from an Asian investor, Medisun International Ltd., which is also committing another €20 million to a joint venture that will take on clinical development and commercialization of its flagship stem cell therapy for ischemic heart failure in the People's Republic of China (PRC), Taiwan and Hong Kong.